{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T23:27:57Z","timestamp":1766186877519,"version":"3.48.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.abd.2025.501220","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:00:58Z","timestamp":1761984058000},"page":"501220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Subacute skin lesions in systemic lupus erythematosus: an impressive and well-tolerated response to anifrolumab"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5820-0609","authenticated-orcid":false,"given":"B\u00e1rbara Fernandes","family":"Esteves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Seabra","family":"Rato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Carlos","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Bernardes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00facia","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel Miriam","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2025.501220_bib0005","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8142368","article-title":"Biologics in the treatment of lupus erythematosus: a critical literature review","volume":"2019","author":"Samotij","year":"2019","journal-title":"Biomed Res Int."},{"key":"10.1016\/j.abd.2025.501220_bib0010","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.3390\/biomedicines11112904","article-title":"Anifrolumab for moderate and severe muco-cutaneous lupus erythematosus: a monocentric experience and review of the current literature","volume":"11","author":"Paolino","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.abd.2025.501220_bib0015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.abd.2025.501220_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2020.1812201","article-title":"Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials","volume":"31","author":"Tanaka","year":"2021","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.abd.2025.501220_bib0025","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti\u2013interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.abd.2025.501220_bib0030","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ad.2024.09.023","article-title":"Anifrolumab for the treatment of refractory cutaneous lupus erythematosus: a Spanish clinical practice-based multicenter study","volume":"116","author":"Mart\u00edn-Torregrosa","year":"2025","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.abd.2025.501220_bib0035","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/acr2.11414","article-title":"Interferon inhibition for lupus with anifrolumab: critical appraisal of the evidence leading to FDA approval","volume":"4","author":"Loncharich","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.abd.2025.501220_bib0040","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomized, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036505962500162X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036505962500162X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T23:25:04Z","timestamp":1766186704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036505962500162X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S036505962500162X"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2025.501220","relation":{},"ISSN":["0365-0596"],"issn-type":[{"type":"print","value":"0365-0596"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subacute skin lesions in systemic lupus erythematosus: an impressive and well-tolerated response to anifrolumab","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2025.501220","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501220"}}